Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Trigeminal neuralgia: from clinical challenges to molecular insights.

The journal of headache and pain·2026

Same author

Intra-mitochondrial glycolysis maintains mitochondrial function and underlies the pathogenesis of retinitis pigmentosa.

Nature communications·2026

Same author

Subtractive Proteomics and Immunoinformatics-Guided Design of a Multi-Epitope Vaccine Against Aspergillus fumigatus.

Probiotics and antimicrobial proteins·2026

Same author

PTBP1 knockdown reprograms glioma stem cells into neuronal-like cells and suppresses tumorigenesis via the DUSP5-ERK1/2 signaling pathway.

Neuro-oncology·2026

Same author

Mapping the global landscape of biofilm-associated antimicrobial resistance (1992-2025).

Biofilm·2026

Same author

Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update.

Cancer letters·2026

Search research articles

Related Experiment Video

Updated: Aug 25, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Molecular profiling identifies distinct subtypes across TP53 mutant tumors.

Xin Chen¹, Tianqi Liu¹, Jianqi Wu¹

¹Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

|October 18, 2022

Summary

Tumor protein 53 mutations (TP53mut) drive cancer, but progression patterns are unclear. This study identifies 5 TP53mut subtypes, revealing distinct features and targeted therapies, including olaparib for the poor-prognosis COCA3 subtype.

Keywords:

Genetics Immunology Immunotherapy p53

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Aug 25, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Oncology
Genomics
Cancer Biology

Background:

TP53 mutations are key drivers of tumorigenesis, yet their role in malignancy progression and distinct molecular subtypes remains incompletely understood.
Understanding the molecular landscape of TP53-mutated cancers is crucial for deciphering tumor development and enabling precise therapeutic strategies.

Purpose of the Study:

To classify TP53-mutated (TP53mut) tumors into distinct subtypes based on integrated genetic and epigenetic features.
To elucidate the unique clinical, genomic, microenvironmental, and therapeutic characteristics of each identified TP53mut subtype.
To identify optimal therapeutic strategies for each subtype, particularly focusing on the COCA3 subtype with the worst prognosis.

Main Methods:

Utilized cluster-of-clusters analysis on genetic and epigenetic alterations in TP53mut cancers.
Performed integrated classification to derive distinct patient subtypes.
Conducted drug efficacy research and in vivo validation for targeted therapies.

Main Results:

Identified 5 distinct subtypes of TP53mut patients with varying genomic alterations, clinical relevance, and microenvironment characteristics.
Designated COCA3 as the subtype with the poorest prognosis, characterized by an immunosuppressive microenvironment and resistance to immunotherapy.
Olaparib demonstrated significant therapeutic potential for COCA3 tumors, while immunotherapy showed efficacy in non-COCA3 subtypes, validated in vivo.

Conclusions:

Developed a multiomics-based subtype classification system for TP53mut tumors, offering distinct targeted therapy strategies.
The classification system enhances understanding of TP53mut tumor development and provides a valuable resource for clinical practice.
This research paves the way for personalized treatment approaches in TP53mut cancers.